FIELD: chemistry.
SUBSTANCE: invention relates to a crystalline form of ilaprazole hydrate (2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulphinyl]-5-(1H-pyrrol-1-yl) 1H-benzimidazole). The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion, as well as a method of treating inflammatory gastrointestinal disorders.
EFFECT: novel crystalline form of ilaprazole hydrate is obtained.
7 cl, 21 dwg, 19 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SOLID FORMS OF RACEMIC ILAPRAZOLE | 2007 |
|
RU2466129C2 |
| MONOHYDRATE OF SODIUM SALT OF S-TENATOPRAZOL AND ITS USE AS INHIBITOR OF PROTON PUMP | 2005 |
|
RU2376304C2 |
| ALKOXY-SUBSTITUTED BENZIMIDAZOLE COMPOUNDS, PHARMACEUTICAL PREPARATIONS COMPRISING THEREOF AND METHOD FOR THEIR USING | 2000 |
|
RU2263673C2 |
| OMEPRAZOL FORM B SODIUM SALT, METHOD OF ITS PREPARING (VERSIONS) AND PHARMACEUTICAL PREPARATION COMPRISING OMEPRAZOL FORM B SODIUM SALT | 1998 |
|
RU2186778C2 |
| (S)-OMEPRAZOLE POTASSIUM SALT, METHOD FOR IT PREPARING AND PHARMACEUTICAL PREPARATION BASED ON THEREOF | 2000 |
|
RU2237666C2 |
| NEW POLYMORPHS OF CALCIUM SALT AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATING AGENTS | 2019 |
|
RU2797511C2 |
| S-OMEPRAZOLE MAGNESIUM SALT TRIHYDRATE, METHODS OF ITS PREPARING, INTERMEDIATE PRODUCT FOR ITS PREPARING, PHARMACEUTICAL COMPOSITION CONTAINING THEREOF AND METHOD OF TREATMENT | 1998 |
|
RU2184115C2 |
| SOLID FORMS OF TTK INHIBITOR | 2017 |
|
RU2753905C2 |
| CRYSTALLINE MODIFICATIONS | 2005 |
|
RU2400479C2 |
| METHOD OF PRODUCING CRYSTALLINE FORM OF MNK INHIBITORS | 2019 |
|
RU2821258C2 |
